South Korea · Research startup
South Korea · Mitoimmune Therapeutics Inc.
MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using mitochondria / ferroptosis based approaches.
Funding reportedLast round: Series B
About Mitoimmune Therapeutics Inc.
MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using mitochondria / ferroptosis based approaches.
Our molecules based on the MIT platform are basically mitochondria-targeted ferroptosis inhibitors which have been demonstrated to recover intracellular homeostasis of iron, calcium, redox, and immune and to preserve antioxidant systems such as GPX4 under pathological conditions where an abnormal increase of mitochondrial reactive oxygen species (ROS) and the accumulation of calcium and iron accumulation occur.
What company datasets say Mitoimmune Therapeutics Inc. raised
Funding, as reported
On a portfolio page
Investors who name them
Each firm lists Mitoimmune Therapeutics Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
biotechnology research
Built with from their website
Microsoft ExchangeMicrosoft 365 Apps & ServicesMicrosoft Exchange OnlineNginxMicrosoft 365OutlookMicrosoft Email Providers
- Sector
- Research
- Full record
- Every detail in the company directory
Research in South Korea
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Mitoimmune Therapeutics Inc. in front of investors. Or tell us what we have wrong.